CDKN2A and breast cancer: In breast cancer, DNA damaging, cytotoxic drugs were shown to trigger TIS based on SA-β-gal staining, p53 and p16INK4a expression in 36 breast cancer samples from patients who received neoadjuvant chemotherapy7.